3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Neoplasms
13
Thyroid Carcinoma, Anaplastic
9
Colorectal Neoplasms
5
Thyroid Cancer, Papillary
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Melanoma
3
Glioma
3
Adenocarcinoma, Follicular
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Nonseminomatous germ cell tumor
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Mouth Neoplasms
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Lymphoproliferative Disorders
1
Interventions
Surveys and Questionnaires
4
Nivolumab
3
pembrolizumab
2
cemiplimab
2
atezolizumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
trametinib
1
repotrectinib
1
pralsetinib
1
pazopanib
1
motexafin gadolinium
1
durvalumab
1
dabrafenib
1
avelumab
1
alectinib
1
Transurethral Resection of Prostate
1
Tomography, X-Ray Computed
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiosurgery
1
Quality of Life
1
Patient-Specific Modeling
1
Oncolytic Virotherapy
1
Ocoxin
1
Observation
1
Mass Screening
1
MLN 8237
1
Immune Checkpoint Inhibitors
1
Hyperspectral Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
trametinib
×
Head & Neck
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled